Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00232752 · ClinicalTrials.gov registry record · Phase 3
Study of the 4.0mm Sirolimus-Eluting Stent in the Treatment of Patients With Coronary Artery Lesions
A Phase 3 study, sponsored by Cordis US.
- Completed
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
NCT00232752 is a Phase 3 study that has completed, run by Cordis US. The registered enrollment target is 100 participants.
The verdict
NCT00232752, a Phase 3 study, has completed, sponsored by Cordis US.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
Study Summary
The main objective of this study is to assess the safety and effectiveness of the sirolimus-eluting Bx VELOCITYTM stent in reducing in-lesion late loss in patients with de novo native coronary artery lesions.
Interventions
- DEVICE 4.0 CYPHER Sirolimus-Eluting Coronary Stent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2003-09 |
| Est. Completion | 2009-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00232752
The ClinicalTrials.gov registry entry for NCT00232752 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cordis US, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 4.0 CYPHER Sirolimus-Eluting Coronary Stent is the first listed.
NCT00232752 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00232752 about?
NCT00232752 is a clinical study titled "Study of the 4.0mm Sirolimus-Eluting Stent in the Treatment of Patients With Coronary Artery Lesions". The main objective of this study is to assess the safety and effectiveness of the sirolimus-eluting Bx VELOCITYTM stent in reducing in-lesion late loss in patients with de novo native coronary artery lesions.
What is the current status of trial NCT00232752?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2003-09. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00232752?
The interventions under investigation include: 4.0 CYPHER Sirolimus-Eluting Coronary Stent (DEVICE).
Who is sponsoring clinical trial NCT00232752?
This trial is sponsored by Cordis US, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.